Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer

H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71, 209–249 (2021)

Google Scholar 

Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Ruschoff, Y.K. Kang, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)

CAS  Google Scholar 

C.C. Volpi, F. Pietrantonio, A. Gloghini, G. Fuca, S. Giordano, S. Corso, G. Pruneri, M. Antista, C. Cremolini, E. Fasano, S. Saggio, S. Faraci, M. Di Bartolomeo, F. De Braud, M. Di Nicola, E. Tagliabue, S.M. Pupa, L. Castagnoli, The landscape of d16HER2 splice variant expression across HER2-positive cancers. Sci. Rep. 9, 3545 https://doi.org/10.1038/s41598-019-40310-5 (2019)

Y.Y. Janjigian, F. Sanchez-Vega, P. Jonsson, W.K. Chatila, J.F. Hechtman, G.Y. Ku, J.C. Riches, Y. Tuvy, R. Kundra, N. Bouvier, E. Vakiani, J. Gao, Z.J. Heins, B.E. Gross, D.P. Kelsen, L. Zhang, V.E. Strong, M. Schattner, H. Gerdes, D.G. Coit, M. Bains, Z.K. Stadler, V.W. Rusch, D.R. Jones, D. Molena, J. Shia, M.E. Robson, M. Capanu, S. Middha, A. Zehir, D.M. Hyman, M. Scaltriti, M. Ladanyi, N. Rosen, D.H. Ilson, M.F. Berger, L. Tang, B.S. Taylor, D.B. Solit, N. Schultz, Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8, 49–58 (2018)

CAS  Google Scholar 

J. Kim, C. Fox, S. Peng, M. Pusung, E. Pectasides, E. Matthee, Y.S. Hong, I.G. Do, J. Jang, A.R. Thorner, P. Van Hummelen, A.K. Rustgi, K.K. Wong, Z. Zhou, P. Tang, K.M. Kim, J. Lee, A.J. Bass, Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. 124, 5145–5158 (2014)

Google Scholar 

S. Stojnev, M. Krstic, A. Ristic-Petrovic, V. Stefanovic, T. Hattori, Gastric cancer stem cells: therapeutic targets. Gastric Cancer 17, 13–25 (2014)

CAS  Google Scholar 

H. Clevers, The cancer stem cell: premises, promises and challenges. Nat. Med. 17, 313–319 (2011)

CAS  Google Scholar 

L. Castagnoli, F. De Santis, T. Volpari, C. Vernieri, E. Tagliabue, M. Di Nicola, S.M. Pupa, Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. Cells 9, E555 (2020)

Google Scholar 

A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Ménard, E. Tagliabue, Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin. Cancer Res. 15, 2010–2021 (2009)

CAS  Google Scholar 

L. Castagnoli, G.C. Ghedini, A. Koschorke, T. Triulzi, M. Dugo, P. Gasparini, P. Casalini, A. Palladini, M. Iezzi, A. Lamolinara, P.L. Lollini, P. Nanni, C. Chiodoni, E. Tagliabue, S.M. Pupa, Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. Oncogene 36, 1721–1732 (2017)

CAS  Google Scholar 

L. Castagnoli, M. Ladomery, E. Tagliabue, S.M. Pupa, The d16HER2 splice variant: a friend or foe of HER2-positive cancers? Cancers 11, 902 (2019)

S.M. Pupa, F. Ligorio, V. Cancila, A. Franceschini, C. Tripodo, C. Vernieri, L. Castagnoli, HER2 signaling and breast cancer stem cells: The Bridge behind HER2-positive breast cnacer aggressiveness and therapy refractoriness. Cancers 13, 4778 (2021)

CAS  Google Scholar 

J. Jiang, Y. Zhang, S. Chuai, Z. Wang, D. Zheng, F. Xu, Y. Zhang, C. Li, Y. Liang, Z. Chen, Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene 31, 671–682 (2012)

CAS  Google Scholar 

D.H. Jung, Y.J. Bae, J.H. Kim, Y.K. Shin, H.C. Jeung, HER2 Regulates Cancer Stem Cell Activities via the Wnt Signaling Pathway in Gastric Cancer Cells. Oncology 97, 311–318 (2019)

CAS  Google Scholar 

X. Rao, C. Zhang, H. Luo, J. Zhang, Z. Zhuang, Z. Liang, X. Wu, Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. Cells 11, 2828 (2022)

CAS  Google Scholar 

C. Saygin, D. Matei, R. Majeti, O. Reizes, J.D. Lathia, Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell 24, 25–40 (2019)

CAS  Google Scholar 

D. Hanahan, Hallmarks of Cancer: New Dimensions. Cancer Discov. 12, 31–46 (2022)

CAS  Google Scholar 

R. Mancini, A. Noto, M.E. Pisanu, C. De Vitis, M. Maugeri-Sacca, G. Ciliberto, Metabolic features of cancer stem cells: the emerging role of lipid metabolism. Oncogene 37, 2367–2378 (2018)

CAS  Google Scholar 

C.Y. Kuo, D.K. Ann, When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance. Cancer Commun. (Lond) 38, 47–0317 (2018)

Google Scholar 

J.A. Menendez, R. Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev. Cancer. 7, 763–777 (2007)

CAS  Google Scholar 

T. Puig, H. Aguilar, S. Cufi, G. Oliveras, C. Turrado, S. Ortega-Gutierrez, B. Benhamu, M.L. Lopez-Rodriguez, A. Urruticoechea, R. Colomer, A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res. 13, R131 (2011)

CAS  Google Scholar 

F. Ligorio, I. Pellegrini, L. Castagnoli, A. Vingiani, R. Lobefaro, E. Zattarin, S.M. Pupa, G. Pruneri, F. De Braud, C. Vernieri, Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapiesin HER2-positive breast cancer. Cancer Lett. 511, 77–87 (2021)

CAS  Google Scholar 

H.E. Li, X. Wang, Z. Tang, F. Liu, W. Chen, Y. Fang, C. Wang, K. Shen, J. Qin, Z. Shen, Y. Sun, X. Qin, A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients. Oncol Lett. 10, 2107–2117 (2015)

CAS  Google Scholar 

M. Apicella, C. Migliore, T. Capelôa, S. Menegon, M. Cargnelutti, M. Degiuli, A. Sapino, A. Sottile, I. Sarotto, L. Casorzo, P. Cassoni, S.M. De, P.M. Comoglio, S. Marsoni, S. Corso, S. Giordano, Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. Oncogene. 36, 1200–1210 (2017)

R.A. Irizarry, B. Hobbs, F. Collin, Y.D. Beazer-Barclay, K.J. Antonellis, U. Scherf, T.P. Speed, Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003)

Google Scholar 

B.S. Carvalho, R.A. Irizarry, A framework for oligonucleotide microarray preprocessing. Bioinformatics 26, 2363–2367 (2010)

CAS  Google Scholar 

J.A. Miller, C. Cai, P. Langfelder, D.H. Geschwind, S.M. Kurian, D.R. Salomon, S. Horvath, Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinformatics. 12, 322. https://doi.org/10.1186/1471-2105-12-322 322–12 (2011)

M.E. Ritchie, B. Phipson, D. Wu, Y. Hu, C.W. Law, W. Shi, G.K. Smyth, limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015)

Google Scholar 

A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, J.P. Mesirov, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci USA 102, 15545–15550 (2005)

CAS  Google Scholar 

G. Korotkevich, V. Sukhov, N. Budin, B. Shpak, M.N. Artyomov, A. Sergushichev, Fast gene set enrichment analysis. bioRxiv, preprint (2021)

A. Liberzon, C. Birger, H. Thorvaldsdόttir, M. Ghandi, J.P. Mesirov, P. Tamayo, The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015)

X. Peng, Z. Chen, F. Farshidfar, X. Xu, P.L. Lorenzi, Y. Wang, F. Cheng, L. Tan, K. Mojumdar, D. Du, Z. Ge, J. Li, G.V. Thomas, K. Birsoy, L. Liu, H. Zhang, Z. Zhao, C. Marchand, J.N. Weinstein, O.F. Bathe, H. Liang, Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep. 23, 255–269 (2018)

CAS  Google Scholar 

I. Shats, M.L. Gatza, J.T. Chang, S. Mori, J. Wang, J. Rich, J.R. Nevins, Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 71, 1772–1780 (2011)

CAS  Google Scholar 

A. Colaprico, T.C. Silva, C. Olsen, L. Garofano, C. Cava, D. Garolini, T.S. Sabedot, T.M. Malta, S.M. Pagnotta, I. Castiglioni, M. Ceccarelli, G. Bontempi, H. Noushmehr, TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016)

Google Scholar 

S. Corso, C. Isella, S.E. Bellomo, M. Apicella, S. Durando, C. Migliore, S. Ughetto, L. D'Errico, S. Menegon, D. Moya-Rull, M. Cargnelutti, T. Capelôa, D. Conticelli, J. Giordano, T. Venesio, A. Balsamo, C. Marchio, M. Degiuli, R. Reddavid, U. Fumagalli, S. De Pascale, G. Sgroi, E. Rausa, G.L. Baiocchi, S. Molfino, F. Pietrantonio, F. Morano, S. Siena, A. Sartore-Bianchi, M. Bencivenga, V. Mengardo, R. Rosati, D. Marrelli, P. Morgagni, S. Rausei, G. Pallabazzer, M. De Simone, D. Ribero, S. Marsoni, A. Sottile, E. Medico, P. Cassoni, A. Sapino, E. Pectasides, A.R. Thorner, A. Nag, S.D. Drinan, B.M. Wollison, A.J. Bass, S. Giordano, A comprehensive PDX gastric cancer collection captures cancer cell-intrinsic transcriptional MSI traits. Cancer Res. 79, 5884–5896 (2019)

A. Sampera, F.J. Sanchez-Martin, O. Arpi, L. Visa, M. Iglesias, S. Menendez, E. Gaye, A. Dalmases, S. Clave, M. Gelabert-Baldrich, T.T. Poulsen, M. Kragh, B. Bellosillo, J. Albanell, A. Rovira, C. Montagut, HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. Mol Cancer Ther. 18, 2135–2145 (2019)

CAS  Google Scholar 

J. Hong, A. Katsha, P. Lu, Y. Shyr, A. Belkhiri, W. El-Rifai, Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. Cancer Res. 72, 4504–4514 (2012)

CAS  Google Scholar 

S. Ughetto, C. Migliore, F. Pietrantonio, M. Apicella, A. Petrelli, L. D’Errico, S. Durando, D. Moya-Rull, S.E. Bellomo, S. Rizzolio, T. Capeloa, S. Ribisi, M. Degiuli, R. Reddavid, I. Rapa, U. Fumagalli, S. De Pascale, D. Ribero, C. Baronchelli, G. Sgroi, E. Rausa, G.L. Baiocchi, S. Molfino, S. Manenti, M. Bencivenga, M. Sacco, C. Castelli, S. Siena, A. Sartore-Bianchi, F. Tosi, F. Morano, A. Raimondi, M. Prisciandaro, A. Gloghini, S. Marsoni, A. Sottile, I. Sarotto, A. Sapino, C. Marchiò, P. Cassoni, S. Guarrera, S. Corso, S. Giordano, Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric. Cancer 24, 897–912 (2021)

CAS  Google Scholar 

A. Vazquez-Martin, R. Colomer, J. Brunet, J.A. Menendez, Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting “HER2 super-expression” occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int. J. Oncol. 31, 769–776 (2007)

CAS  Google Scholar 

A. Gruslova, B. McClellan, H.U. Balinda, S. Viswanadhapalli, V. Alers, G.R. Sareddy, T. Huang, M. Garcia, L. deGraffenried, R.K. Vadlamudi, A.J. Brenner, FASN inhibition as a potential treatment for endocrine-resistant breast cancer. Breast Cancer Res Treat. 187, 375–386 (2021)

D.Y. Oh, Y.J. Bang, HER2-targeted therapies - a role beyond breast cancer. Nat. Rev. Clin Oncol. 17, 33–48 (2020)

CAS  Google Scholar 

K. Dzobo, D.A. Senthebane, A. Rowe, N.E. Thomford, L.M. Mwapagha, N. Al-Awwad, C. Dandara, M.I. Parker, Cancer stem cell hypothesis for therapeutic innovation in clinical oncology? taking the root out, not chopping the leaf. OMICS 20, 681–691 (2016)

CAS  Google Scholar 

J.A. Menendez, T. Alarcon, Metabostemness: a new cancer hallmark. Front. Oncol. 4, 262 (2014)

Google Scholar 

H. Li, Z. Feng, M.L. He, Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells. Theranostics. 10, 7053–7069 (2020)

CAS  Google Scholar 

Y. Yasumoto, H. Miyazaki, L.K. Vaidyan, Y. Kagawa, M. Ebrahimi, Y. Yamamoto, M. Ogata, Y. Katsuyama, H. Sadahiro, M. Suzuki, Y. Owada, Inhibition of Fatty Acid Synthase Decreases Expression of Stemness Markers in Glioma Stem Cells. PLoS One 11, e0147717 (2016)

Google Scholar 

J. Brandi, I. Dando, E.D. Pozza, G. Biondani, R. Jenkins, V. Elliott, K. Park, G. Fanelli, L. Zolla, E. Costello, A. Scarpa, D. Cecconi, M. Palmieri, Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. J. Proteomics. 150, 310–322 (2017)

CAS  Google Scholar 

P.R. Pandey, H. Okuda, M. Watabe, S.K. Pai, W. Liu, A. Kobayashi, F. Xing, K. Fukuda, S. Hirota, T. Sugai, G. Wakabayashi, K. Koeda, M. Kashiwaba, K. Suzuki, T. Chiba, M. Endo, T. Fujioka, S. Tanji, Y.Y. Mo, D. Cao, A.C. Wilber, K. Watabe, Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat. 130, 387–398 (2011)

CAS  Google Scholar 

J.A. Menendez, R. Lupu, Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin. Ther. Targets. 21, 1001–1016 (2017)

CAS  Google Scholar 

P. Farhadi, R. Yarani, E. Valipour, S. Kiani, Z. Hoseinkhani, K. Mansouri, Cell line-directed breast cancer research based on glucose metabolism status. Biomed. Pharmacother. 146, 112526 (2022)

CAS  Google Scholar 

Y.Y. Zaytseva, J.W. Harris, M.I. Mitov, J.T. Kim, D.A. Butterfield, E.Y. Lee, H.L. Weiss, T. Gao, B.M. Evers, Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration. Oncotarget 6, 18891–18904 (2015)

Google Scholar 

P.M.R. Pereira, S.K. Sharma, L.M. Carter, K.J. Edwards, J. Pourat, A. Ragupathi, Y.Y. Janjigian, J.C. Durack, J.S. Lewis, Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat. Commun. 9, 5137 (2018)

Google Scholar 

留言 (0)

沒有登入
gif